Pre-clinical studies have also explored the indirect targeting of SREBPs through their activating protein, SCAP. SCAP inhibition demonstrated significant anti-tumor efficacy, including impaired tumor progression in mouse models, suggesting alternative strategies to modulate SREBP activity in vivo.126 Furthermore, natural compounds that inhibit SREBP signaling have also shown therapeutic potential in pancreatic cancer. The gene discussed is SCAP; the disease is neoplasm.